Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

265results about How to "Good skin permeability" patented technology

Ultrasound enhancement of percutaneous drug absorption

InactiveUS7004933B2Easy to transportLittle and no side effectSurgeryMedical devicesMedicineActive agent
A system for enhancing and improving the transcutaneous or transdermal delivery of topical chemicals or drugs. A disposable container contains a substantially sterile unit dose of an active agent adapted for a single use in a medical treatment. The unit dose is formulated to enhance transport of the active agent through mammalian skin when the active agent is applied to the skin and the skin is exposed to light and / or ultrasound defined by at least one specific parameter.
Owner:LOREAL SA

Active transdermal drug delivery system and the method thereof

The present invention relates to an active transdermal drug delivery system performing transdermal drug delivery comprising of a patch capable of being attachable to the skin of the subject; at least one electrical energy power input; a plurality of converters / energy transducers configured for converting the electrical energy to different forms of energy; and a controller including a programmable microprocessor configured for providing the intensity, sequence, nature, and timing information for the different energies supplied and thereby providing activating signals to the said converters for the transdermal drug delivery by the said patch, and a method for performing transdermal drug delivery using said electronic patch.
Owner:ITRACE BIOMEDICAL

Microneedle Device And Transdermal Administration Device Provided With Microneedles

The present invention provides a microneedle device having a coating, which is effective even with a low molecular weight active compound and can sustain the effect of the drug for a long period of time, and a transdermal drug administration apparatus with microneedles. The microneedle device (5) has, on a microneedle substrate (8), a plurality of microneedles (6) that can pierce the skin, wherein the surface of the microneedles (6) and / or the microneedle substrate (8) is partly or entirely coated in fixed state with a coating carrier containing polyvinyl alcohol. The polyvinyl alcohol preferably has a hydrolysis degree of 94.5 mol % or more. Furthermore, the coating carrier can contain a drug.
Owner:HISAMITSU PHARM CO INC

Topical skin composition and method for moisturizing the skin

A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise Saccharomyces zinc ferment, Saccharomyces copper ferment, Saccharomyces magnesium ferment, Saccharomyces iron ferment, Saccharomyces silicon ferment, and Saccharomyces calcium ferment in equal amounts, more preferably from approximately 0.05% to approximately 0.15% by weight of each component. The humectant blend preferably comprises glycerin, beet root extract, and Aloe barbadensis leaf polysaccharides.
Owner:BEAUTYAVENUES

Photokinetic delivery of biologically active substances using pulsed incoherent light

The invention relates generally to transdermal and transmembrane delivery of biologically active substances through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular surface, tissue or membrane. The invention provides compositions and methods for enhanced transdermal and transmembrane delivery of biologically active substances using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes using those compositions and methods.
Owner:PHOTOKINETIX HLDG

Transdermal therapeutic system

A therapeutic system for supplying active substances to the skin consists of a backing layer remote from the skin, with at least one active substance depot. The depot may consist of a fluid active substance or a fluid composition comprising an active substance delivery control matrix. There is also included an adhesive fixing device for fixing the therapeutic system on the skin. The therapeutic system is characterized in that the active substance depots (14) consist of at least one adjuvant having a supporting and distributing function by being provided with a planar textile material completely surrounded by matrix (12).
Owner:LTS LOHMANN THERAPIE-SYST AG

Adhesive patch

A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with a drug and an adhesive base agent, wherein the adhesive base agent comprises styrene-isoprene-styrene block copolymer, 2-ethylhexyl acrylatevinyl acetate copolymer and a basic nitrogen-including polymer including a basic nitrogen and having no adhesion property at normal temperature.
Owner:HISAMITSU PHARM CO INC

Skin Care Applicator

InactiveUS20180264245A1Reduce of minimum magnetic flux density magneticReduce of magnetic ineffectual magnetic field strengthCosmetic preparationsElectrotherapyMagnetic polesUltimate tensile strength
An applicator for a skin care product is provided, together with a cosmetic skin care product comprising an applicator and a skin care composition, and a method of using the applicator to regulate a skin condition. The applicator has a substrate with a magnetic array printed thereon, the magnetic array having at least one layer of one or more dipolar pairs of alternating magnetic poles. The applicator further has a vibration source. The magnetic field strength generated by the magnetic array is at its maximum at the poles. When activated, the vibration source causes side to side movement of the applicator, meaning that the full magnetic field is experienced by all diamagnetic materials to which the applicator is applied.
Owner:THE PROCTER & GAMBLE COMPANY

Active transdermal drug delivery system and the method thereof

The present invention relates to an active transdermal drug delivery system performing transdermal drug delivery comprising of a patch capable of being attachable to the skin of the subject; at least one electrical energy power input; a plurality of converters / energy transducers configured for converting the electrical energy to different forms of energy; and a controller including a programmable microprocessor configured for providing the intensity, sequence, nature, and timing information for the different energies supplied and thereby providing activating signals to the said converters for the transdermal drug delivery by the said patch, and a method for performing transdermal drug delivery using said electronic patch.
Owner:ITRACE BIOMEDICAL

Method of exfoliation

Method of exfoliating mammalian skin comprising the step of using a foam applicator to apply a personal care composition to delicate mammalian skin, wherein the foam applicator comprises a material selected from the group consisting of polyester, polyurethane, polyether, polyethylene, polystyrene, cross-linked polyethylene, and mixtures thereof, and has a porosity of from about 10 to about 110 pores per square inch; and wherein the personal care composition comprises a dermatologically-acceptable carrier in the form of an emulsion.
Owner:THE PROCTER & GAMBLE COMPANY

Protein nanocarriers for topical delivery

The invention encompasses nanoparticle assemblies and methods for preparing nanoparticle and compositions comprising such nanoparticles for use in topical or skin applications. The invention further encompasses methods of complexing various molecular and cellular entities to the nanoparticles using the resulting nanoparticles of the invention as delivery devices. The nanoparticles can be used for a variety of applications, such as treating cancer, targeting tumors, reducing the toxicity of a drug in vivo, increasing the efficacy of a complexed agent in vivo, protecting a complexed agent against degradation, increasing skin penetration and retention of drugs, and enhancing the water solubility / dispersibility of a drug or other agent.
Owner:SOUTH DAKOTA STATE UNIVERSITY

Screening method and compounds for treating friedreich ataxia

InactiveUS20050222218A1Reducing cellular glutathione contentGood skin permeabilityBiocideCompound screeningMedicineFrataxin
The present invention relates to a method for identifying and / or validating candidate substances for the treatment of Friedreich Ataxia (FRDA). Furthermore, the present invention relates to the use of selenium, Ebselen and Glutathione peroxidase (GPX) mimetics for the preparation of a medicament for the treatment of FRDA. Another aspect of the present invention relates to the use of cells with reduced frataxin expression for identifying and / or validating candidate substances for the treatment of Friedreich Ataxia.
Owner:SANTHERA PHARMA SCHWEIZ

Method of promoting the penetration of a cosmetic active and composition therefore

The invention relates to a method of promoting the penetration of a cosmetic active, wherein a composition in the form of a water-in-oil emulsion is applied topically, said emulsion comprising a fatty phase with a polarity ba greater than or equal to 0.1 and comprising a mixture of at least two oils, and in that the application of said emulsion is made simultaneously, with an interval or sequentially in time with the application of the cosmetic active.
Owner:LOREAL SA

Cosmetic compositions

The present invention generally features novel cosmetic skin and hair care compositions for enhancing the appearance of eyelashes and eyebrows. Specifically, the topical skin and hair care compositions of the invention contain a concentration of at least one of pentapeptide-17 tetrapeptide-12 that provide for thicker, longer and more voluminous appearing eyelashes and eyebrows. The cosmetic formulations of the invention may further include cosmetically acceptable vehicle(s) and / or other skin and hair conditioning agents.
Owner:JAN MARINI SKIN RES

Dermatological compositions comprising avermectin nanocapsules

Compositions and nanoemulsions containing lipid nanocapsules dispersed in a hydrophilic phase, such nanocapsules including at least one avermectin compound, are useful for the treatment of dermatological pathologies, e.g., rosacea.
Owner:GALDERMA HLDG SA

Medical Uses of Carrier Conjugates of Non-Human Tnf -Peptides

The present invention is related to the fields of molecular biology, virology, immunology and medicine. The invention provides a modified virus-like particle (VLP) comprising—a VLP and a particular peptide derived from a polypeptide from the TNF-superfamily linked thereto for use in the production of vaccines for the treatment of autoimmune diseases and bone-related diseases and to efficiently induce immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.
Owner:CYTOS BIOTECHNOLOGY AG

Emulsified composition

The emulsion composition of the present invention contains(A) 0.001 to 10 wt. % of an organic compound having two or more hydroxyl groups, an inorganic value of 220 to 450, and an organic value of 300 to 1,000;(B) 0.001 to 10 wt. % of an organic compound having one hydroxyl group, an inorganic value of 100 to 200, and an organic value of 280 to 700;(C) 0.001 to 10 wt. % of a compound represented by formula (2):wherein R1 is a C4 to C30 hydrocarbon group; Z is a methylene group, a methine group, or an oxygen atom; X1, X2, X3 is a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 is a hydrogen atom, an acetyl group, or a glyceryl group; each of R2 and R3 a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; R4 is a C5 to C60 hydrocarbon group; and R5 is a hydrogen atom or a hydrocarbon group containing 1 to 30 carbon atoms in total;(D) 0.00012 to 10 wt. % of at least one compound selected from the group consisting of a nonionic surfactant having a polyoxyethylene group and an HLB of 10 or higher, an ionic surfactant, and a sphingosine salt;(E) 0.003 to 15 wt. % of at least one compound selected from the group consisting of a sugar alcohol selected from the group consisting of erythritol, threitol, xylitol, and mannitol, a disaccharide, and a trisaccharide; and(F) water.
Owner:KAO CORP

Skin-friendly drug complexes for transdermal administration

The present invention generally relates to pharmaceutical compositions for the treatment of various diseases and disorders, in particular the use of novel complexes of amine drugs with polyacrylic acid carbomer polymers. The compositions of the present invention can be administered transdermally or transmucosally to patients in need thereof for a systemic or for a local therapeutic effect. The compositions of the present invention present the additional benefits of being free or substantially free of excipients which may potentially be responsible for skin local reactions and unpleasant smell.
Owner:ANTARES PHARMA IPL

Ionic liquids for transdermal drug delivery

ActiveUS20160263225A1Inhibit transferDirect and prevent transportAntibacterial agentsBiocideBiofilmDisease
The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
Owner:TRIAD NAT SECURITY LLC +2

Ghrelin-carrier conjugates

The present invention provides ordered and repetitive antigen arrays comprising, inter alia, compositions comprising a virus-like particle (VLP) to which is linked at least one antigen, wherein said antigen is grehlin or peptides or fragments thereof. The invention also provides methods for producing the aforesaid compositions. The compositions and methods of the invention are useful in the production of vaccines and to efficiently induce self-specific immune responses, in particular antibody responses. The invention also provides for compositions and methods for the prevention and / or treatment of ghrelin-related conditions, disorders or diseases. For example, the compositions of the invention are useful in the production of vaccines for the prevention or treatment of obesity and other disease associated with increased food-uptake or increased body weight.
Owner:CYTOS BIOTECHNOLOGY AG

Emulsified composition

The emulsion composition of the present invention contains(A) 0.001 to 10 wt. % of an organic compound having two or more hydroxyl groups, an inorganic value of 220 to 450, and an organic value of 300 to 1,000;(B) 0.001 to 10 wt. % of an organic compound having one hydroxyl group, an inorganic value of 100 to 200, and an organic value of 280 to 700;(C) 0.001 to 10 wt. % of a compound represented by formula (2):wherein R1 is a C4 to C30 hydrocarbon group; Z is a methylene group, a methine group, or an oxygen atom; X1, X2, X3 is a hydrogen atom, a hydroxyl group, or an acetoxy group; X4 is a hydrogen atom, an acetyl group, or a glyceryl group; each of R2 and R3 a hydrogen atom, a hydroxyl group, a hydroxymethyl group, or an acetoxymethyl group; R4 is a C5 to C60 hydrocarbon group; and R5 is a hydrogen atom or a hydrocarbon group containing 1 to 30 carbon atoms in total;(D) 0.00012 to 10 wt. % of at least one compound selected from the group consisting of a nonionic surfactant having a polyoxyethylene group and an HLB of 10 or higher, an ionic surfactant, and a sphingosine salt;(E) 0.003 to 15 wt. % of at least one compound selected from the group consisting of a sugar alcohol selected from the group consisting of erythritol, threitol, xylitol, and mannitol, a disaccharide, and a trisaccharide; and(F) water.
Owner:KAO CORP

Topical skin composition comprising mineral yeast ferments

A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise Saccharomyces zinc ferment, Saccharomyces copper ferment, Saccharomyces magnesium ferment, Saccharomyces iron ferment, Saccharomyces silicon ferment, and Saccharomyces calcium ferment in equal amounts, more preferably from approximately 0.05% to approximately 0.15% by weight of each component. The humectant blend preferably comprises glycerin, beet root extract, and Aloe barbadensis leaf polysaccharides.
Owner:BEAUTYAVENUES

Alcohol based topical anesthetic formulation and method

A method for applying a topical anesthetic to an area of skin comprising the steps of a) incorporating an anesthetic in a lipophilic base into a volatile solvent, to form a homogeneous solution; b) applying the homogeneous solution into the area of skin to be treated; and c) evaporating the volatile solvent from the homogeneous solution; wherein the volatile solvent is present in the formulation in amounts between 40-80%; and wherein said topical anesthetic rapidly penetrates the skin surface at said skin, leaving a cooling sensation on the skin. The topical anesthetic formulation contains a penetrating enhancer carrier that markedly enhances the delivery of the anesthetic across human skin without altering the acceptable delivery rate of the anesthetic that needs to be delivered through the skin and leaves a cooling sensation on the skin.
Owner:CASTILLO JAMES G

A nanoemulsion medicine of eugenol and preparation method thereof

The invention discloses the eugenic nanometer drug, comprising isopropyl microstate, croton oil, vitamin E oil, tuwen-80, spans-80 and eugenic. The drug has the advantages of improving the antibiosis, anti-inflammation, disinfection, analgesic, and ant parasitic. So the drug is green, safe and highly effective ant parasitic agent.
Owner:NORTHWEST A & F UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products